| Literature DB >> 28841919 |
Hiroka Ando1, Yuko Watanabe2, Minori Ogawa2, Hiromi Tamura3, Tomomi Deguchi2, Kayo Ikeda2, Mayumi Fujitani2, Mitsunori Shioji2, Tomoko Tsujie2, Reiko Doi3, Akinori Wakimoto2, Shiro Adachi3.
Abstract
BACKGROUND: Mesonephric adenocarcinoma (MA) is a rare tumor believed to arise from mesonephric remnants occurring mostly in the uterine cervix and, to a lesser extent, the corpus. Since the first case report of MA in the corpus in 1995, only 16 cases have been reported in the English literature. A recent report suggested that MA originates in Müllerian tissue and exhibits the mesonephric differentiation phenotype. CASEEntities:
Keywords: Intracystic growth; Mesonephric adenocarcinoma; Uterine corpus
Mesh:
Year: 2017 PMID: 28841919 PMCID: PMC6389062 DOI: 10.1186/s13000-017-0655-y
Source DB: PubMed Journal: Diagn Pathol ISSN: 1746-1596 Impact factor: 2.644
Fig. 1a Macroscopic view of the resected specimen. An intramural polypoid tumor protrudes from the incision of the lateral wall of the corpus (arrow). The cervical-endocervical canal and corpus cavity are observed to the right of the incision. An endometrial polyp is observed (arrowhead). The endometrium and endocervical mucosa are not involved. b Sagittal section of the uterus (a cross-section of the line in Fig. 1a). The arrow indicates the edge of the endometrial cavity. The yellow-white polypoid tumor appears to be situated in the cyst within the myometrial layer. The tumor invades the posterior wall of the corpus transmurally. A leiomyoma nodule is observed immediately to the left
Fig. 2Hematoxylin and eosin staining. a Panoramic view of the tumor. The left half of the tissue is the intracystic component, and the right half is the invasive component in the myometrial layer. b Relatively uniform tubules containing dense eosinophilic secretion is characteristic. c Tumor cells within the eosinophilic cytoplasm are lined in an acinar fashion. d Tumor cells show a very high nuclear-cytoplasmic ratio in a solid pattern. e Invasive carcinoma in the myometrium. Much higher-grade carcinoma similar to conventional endometrioid adenocarcinoma invades the myometrial layer
Immunohistochemical staining results
| Antibody (Manufacture) | Tubular | Acinar | Solid | Ductal |
|---|---|---|---|---|
| CK7 (Roche) | 4+ | 4+ | 3+ | 3+ |
| CK20 (Roche) | 0 | 0 | 0 | 0 |
| CD10 (Roche) | 4+ | 0 | 0 | 2+ |
| Vimentin (Roche) | 4+ | 4+ | 0 | 2+ |
| Calretinin (Roche) | 2+ | 0 | 0 | 1+ |
| GATA3 (Nichirei) | 2+ | 0 | 0 | 1+ |
| Inhibin (DAKO) | 0 | 0 | 0 | 0 |
| ER (Roche) | 1+ | 0 | 0 | 0 |
| PR (Roche) | 0 | 0 | 0 | 0 |
| p16 (Roche) | 2+ | 2+ | 2+ | 4+ |
| PAX8 (BIOCARE) | 4+ | 4+ | 4+ | 4+ |
| CA125 (DAKO) | 4+ | 1+ | 4+ | 3+ |
| CA19–9 (Roche) | 3+ | 1+ | 2+ | 2+ |
| TTF1 (Roche) | 4+ | 4+ | 0 | 2+ |
| Napsin (Roche) | 1+ | 0 | 0 | 0 |
| WT1 (Roche) | 0 | 0 | 0 | 0 |
| Ki67 (Roche) | 4% | 3% | 40% | 50% |
| p53 (Roche) | 0 | 0 | 0 | 0 |
0: 0; 1+: <1% positive cells, 2+: 1–10% positive cells; 3+: 10–50% positive cells; 4+: >50% positive cells; Ki67: Ki67 labeling index
Fig. 3Immunohistochemical staining of the tumor. a Luminal expression of CD10 in the neoplastic tubules is observed focally. b Focal cytoplasmic and nuclear expression of calretinin. c Focal and weak expression of GATA3. d Vimentin shows diffuse expression in the acinar pattern but lacks expression in the solid pattern. e and f, respectively In the tubular pattern, many tumor cells express CA125 and CA19–9
Reported cases of mesonephric adenocarcinoma in the uterine corpus
| Case | Study | Age | Size(cm) | Mesonephric remnant | Location | Involvement of END | CA125 | CA19–9 |
|---|---|---|---|---|---|---|---|---|
| 1 | Yamamoto et al. [ | 58 | 14 | Cervix | MYO (left lateral) | - | Normal | Normal |
| 2 | Ordi et al. [ | 33 | 8 × 6 | - | MYO | - | 47 IU/mL | NA |
| 3 | Bagué et al. [ | 37 | 3.5 | - | END | + | NA | NA |
| 4 | Marquette et al. [ | 81 | 3.7 × 3.0 × 2.3 | NA | MYO (right lateral) | + | 55 kU/mL | NA |
| 5 | Wani et al. [ | 73 | 8 × 7 | - | MYO | + | Normal | Normal |
| 6 | Kenny et al. [ | NA | NA | cervix | corpus | NA | NA | NA |
| 7 | Wu et al. [ | 55 | 3.5 × 2.5 × 2.0 | NA | MYO, endocervix, (lateral) | + | 163.8 U/mL | 193.6 U/mL |
| 8 | Wu et al. [ | 62 | 8 × 7 × 3 | NA | MYO | NA | Normal | Normal |
| 9–15 | McFarland et al. [ | NA | NA | - | END, subsequent to MYO | + | NA | NA |
| 16 | Kim et al. [ | 66 | 2.5 × 2.0 | - | MYO (left anterolateral) | + | Normal | NA |
| 17 | Ando et al. (present case) | 61 | 8 × 6.5 | - | MYO (left posterolateral) | - | 389 U/mL | 785 U/mL |
END endometrium, MYO myometrium of the uterine corpus, NA not available